Mkts

Inhibikase Therapeutics, Inc.

NASDAQ: IKT
$1.55-0.12 (-7.19%)
As of Oct 30, 4:00 PM ET

Key statistics

Day range
1.521.67
52-week range
1.332.61
Today
Open1.67
Previous close1.55
Volume917.2K
Valuation
Market cap216.28M
P/E ratio—
EPS (TTM)-0.50
Income & risk
Dividend / yield—
Beta0.92
Avg volume725.5K
Discussion

IKT News

Stories mentioning IKT from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold
Gross Profit
Operating Expenses
Research & Development10,8396,3587,6505,27110,5147,1944,1903,076
Sales General & Admin7,3766,7745,6125,9205,2495,7351,6381,975
Total Operating Expenses
Operating Income (Loss)(17,842)(13,776)(12,768)(10,832)(14,598)(12,929)(5,827)(5,051)
Interest Income
Interest Expense
Other Expense
Pretax Income
Tax Provision0.000.000.000.000.000.000.000.00
Net Income (Loss)(16,381)(12,734)(11,930)(9,916)(13,679)(12,132)(5,778)(4,960)
Earnings Per Share (Basic)(0.10)(0.13)(0.13)(0.11)(0.15)(0.51)(0.65)(0.66)
Earnings Per Share (Diluted)(0.10)(0.13)(0.13)(0.11)(0.15)(0.51)(0.65)(0.66)
Weighted Average Shares Outstanding (Basic)172,30798,31090,05190,01089,53723,7128,8837,536
Weighted Average Shares Outstanding (Diluted)172,30798,31090,05190,01089,53723,7128,8837,536

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About IKT

Inhibikase Therapeutics, Inc. (NASDAQ: IKT) is a stock listed on the Nasdaq Stock Market under the ticker symbol IKT. It last traded at $1.55 (Oct 30, 2026, 4:00 PM ET), down 7.2% on the day. That gives Inhibikase Therapeutics a market capitalisation of $216.3M.

Over the past 52 weeks IKT has traded between $1.33 and $2.61.

Revenue for the quarter ended Mar 31, 2026 was $0; a net loss of $16.4M.

Last 4 quarters
Quarter endedRevenueNet income
Mar 31, 2026$0-$16.4M
Dec 31, 2025$0-$12.7M
Sep 30, 2025$0-$11.9M
Jun 30, 2025$0-$9.9M

From Inhibikase Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…